Atara Biotherapeutics Inc (ATRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.77 (+0.62%), Market cap $0.08B, 52-week low–high $4.18 ~ $18.09.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Resea
Financial statements, price targets, institutional (13F) holdings and related news for Atara Biotherapeutics Inc are updated in real time on BlackAll Trade.
Atara Biotherapeutics Inc trades at $9.77 (+0.62%). Real-time quotes and charts are available on BlackAll Trade.
Atara Biotherapeutics Inc has a market cap of about $0.08B.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes T